Biocon, HCG Group of Hospitals Collaborate To Fight Cervical Cancer

India-based Biocon and HCG group of Hospitals have announced their partnership to conduct a study to evaluate the potential benefits of BIOMAb EGFR in cervical cancer patients. The molecule is expected to take healthcare for cervical cancer patients to a new threshold.

BIOMAb EGFR is Biocon’s humanized monoclonal antibody which is approved for the treatment of head and neck cancers in India.

The study will be conducted for six years in various centers of HCG across the country, involving many eminent oncologists and will be in compliance to ICH-GCP guidelines. The participating centers are Bangalore, Mysore, Vijayavada, Ranchi, Cuttak and Nasik (all in India).

Kiran Mazumdar Shaw, MD of Biocon, said: “This partnership is in light of the unmet need for an effective treatment option for the large number of cervical cancer patients in our country. I see this collaborative model of Biocon’s unique humanized MAb and HCG’s state of the art facilities as a big step towards developing India as a global destination for translation research and cutting edge clinical trials.”

Ajai Kumar, chairman and CEO of HCG, said: “this HCG-led study will be conducted in a well conducted in a well controlled manner specifically keeping in mind the needs of the Indian patients which vary considerably from those of the West. Most treatment for this disease is currently based on data obtained from the western world.

“We chose BIONMAb EGFR taking into account the safety profile this molecule has displayed I addition to results obtained in the other studies with this drug.”